| P50 | author | Donald K. Ingram | Q107733297 |
| | Johan Sandin | Q50637797 |
| P2093 | author name string | Nigel H Greig | |
| | Joseph A Araujo | |
| | Christina de Rivera | |
| | Norton W Milgram | |
| P2860 | cites work | The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates. | Q51973289 |
| | Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. | Q51997691 |
| | Visuospatial impairments in aged canines (Canis familiaris): the role of cognitive-behavioral flexibility. | Q52012363 |
| | Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. | Q52020724 |
| | Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. | Q52039414 |
| | Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. | Q52042629 |
| | Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. | Q52045840 |
| | Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. | Q52054155 |
| | The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. | Q52060302 |
| | Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. | Q52064446 |
| | Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. | Q52132865 |
| | Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. | Q52189958 |
| | An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors. | Q52201942 |
| | Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. | Q53192718 |
| | Cognitive and behavioral sensitivity to scopolamine in Alzheimer patients and controls. | Q53195328 |
| | Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases. | Q53198385 |
| | Scopolamine model of dementia: electroencephalogram findings and cognitive performance. | Q53225073 |
| | Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs | Q71594507 |
| | Locomotor activity rhythms in dogs vary with age and cognitive status | Q73835824 |
| | The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. | Q37354760 |
| | Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders | Q37354764 |
| | Phenserine Efficacy in Alzheimer's Disease | Q37510264 |
| | The canine as a model of human cognitive aging: recent developments | Q38441952 |
| | Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study | Q38489258 |
| | Pharmacologic modelling of Alzheimer's disease | Q39753042 |
| | Cholinergic receptors in aging and Alzheimer's disease | Q39753054 |
| | Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue | Q39835119 |
| | Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging | Q39897525 |
| | The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. | Q40227332 |
| | Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide | Q40281052 |
| | Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis | Q40653119 |
| | Central Anticholinergic Hypersensitivity in Aging | Q41084079 |
| | Scopolamine challenges in Alzheimer's disease | Q41490389 |
| | Possible role of the cholinergic system and disease models. | Q41573860 |
| | Region-specific age at onset of beta-amyloid in dogs | Q41733900 |
| | Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. | Q42498874 |
| | Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease | Q42646408 |
| | Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density | Q42757338 |
| | Magnetic resonance imaging of anatomic and vascular characteristics in a canine model of human aging | Q43405668 |
| | Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia | Q44039758 |
| | Oxidative damage increases with age in a canine model of human brain aging | Q44068708 |
| | Dietary enrichment counteracts age-associated cognitive dysfunction in canines | Q44188916 |
| | Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients | Q44265136 |
| | Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease | Q44466201 |
| | Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination | Q44804443 |
| | Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys | Q45020579 |
| | Nicotinic and muscarinic cholinergic receptors in Alzheimer's disease and related disorders | Q45030829 |
| | The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats | Q45202745 |
| | Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine | Q46089691 |
| | Visual-discrimination learning ability and beta-amyloid accumulation in the dog. | Q46235992 |
| | Application of an automated voxel-based morphometry technique to assess regional gray and white matter brain atrophy in a canine model of aging | Q46245858 |
| | Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans | Q46475895 |
| | Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects | Q46774121 |
| | A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. | Q46813624 |
| | Changes in brain cholinesterases in senile dementia of Alzheimer type | Q48176243 |
| | Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks | Q48179028 |
| | Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning | Q48262827 |
| | Necropsy evidence of central cholinergic deficits in senile dementia | Q48319379 |
| | Selective loss of central cholinergic neurons in Alzheimer's disease | Q48342983 |
| | Brain muscarinic receptors in senile dementia | Q48479457 |
| | Diffuse beta-amyloid plaques and hyperphosphorylated tau are unrelated processes in aged dogs with behavioral deficits | Q48496234 |
| | Visuospatial function in the beagle dog: an early marker of cognitive decline in a model of human aging and dementia | Q48583221 |
| | Human memory and the cholinergic system. A relationship to aging? | Q48584703 |
| | Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease | Q48654715 |
| | Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions | Q48696243 |
| | Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze | Q48824371 |
| | The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics | Q48944505 |
| | Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 |
| | Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein | Q24302890 |
| | Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction | Q28111935 |
| | The cholinergic hypothesis of geriatric memory dysfunction | Q28277644 |
| | Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease | Q28287090 |
| | A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 |
| | The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region | Q30776788 |
| | Donepezil. Pharmacoeconomic implications of therapy | Q33761849 |
| | The beta-amyloid precursor protein and its derivatives: from biology to learning and memory processes | Q33863439 |
| | Neuroprotective effects of cognitive enrichment | Q33999196 |
| | Spatial learning and memory as a function of age in the dog. | Q34370735 |
| | Why so few drugs for Alzheimer's disease? Are methods failing drugs? | Q34440659 |
| | Landmark discrimination learning in the dog. | Q35039179 |
| | Effect of age and level of cognitive function on spontaneous and exploratory behaviors in the beagle dog | Q35042013 |
| | Current treatments for Alzheimer's disease: cholinesterase inhibitors. | Q35205238 |
| | Effects of age on measures of complex working memory span in the beagle dog (Canis familiaris) using two versions of a spatial list learning paradigm | Q35974291 |
| | Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging | Q36082211 |
| | The canine model of human cognitive aging and dementia: pharmacological validity of the model for assessment of human cognitive-enhancing drugs | Q36082227 |
| | Behavior problems in geriatric pets. | Q36099805 |
| | An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease | Q36172619 |
| | Assessment of nutritional interventions for modification of age-associated cognitive decline using a canine model of human aging | Q36272892 |
| | Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development | Q36318080 |
| | Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function | Q36325260 |
| | Region specific neuron loss in the aged canine hippocampus is reduced by enrichment | Q36380222 |
| | Therapeutic options for cognitive decline in senior pets | Q36646583 |
| | Phenserine | Q36861622 |
| | Anti-dementia drugs and hippocampal-dependent memory in rodents | Q36925129 |
| | Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease | Q37207763 |
| | Animal models of Alzheimer's disease: therapeutic implications. | Q37354734 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 143-155 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs | |
| P478 | volume | 26 | |